- Home
- BST vs RAPP Comparison
BST vs RAPP Comparison
Compare BST & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BST | RAPP |
|---|---|---|
| Founded | 2014 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2014 | 2024 |
Fundamental Metrics
Financial Performance| Metric | BST | RAPP |
|---|---|---|
| Price | $48.36 | $41.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $48.50 |
| AVG Volume (30 Days) | 93.4K | ★ 463.5K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.87 | $13.43 |
| 52 Week High | $51.30 | $43.76 |
Technical Indicators
Market Signals| Indicator | BST | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 60.37 |
| Support Level | $47.20 | $33.54 |
| Resistance Level | $50.41 | $43.76 |
| Average True Range (ATR) | 1.20 | 2.75 |
| MACD | -0.21 | 0.22 |
| Stochastic Oscillator | 27.20 | 68.94 |
Price Performance
Historical ComparisonAbout BST BlackRock Science and Technology Trust of Beneficial Interest
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objectives are to provide total return and income through long-term capital appreciation.
About RAPP Rapport Therapeutics Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.